BACKGROUND: African adults infected with human immunodeficiency virus (HIV) have high rates of pneumococcal colonization and invasive disease. Here we have investigated the possibility that HIV disrupts the normal balance of pneumococcal-specific helper T cell (Th) 1/Th17 immunity to colonization, resulting in a more permissive nasopharyngeal niche. METHODS: One hundred thirty-six HIV-infected and -uninfected Malawian adults were enrolled in the study. Changes in rates and composition of nasopharyngeal pneumococcal colonization were analyzed using microarray. The underlying pneumococcal-specific Th1/Th17 responses associated with altered pneumococcal colonization were investigated using flow cytometry. RESULTS: We find that pneumococcal carriage is only modestly increased in asymptomatic HIV-infected Malawian adults but that colonization rates rise dramatically during symptomatic disease (HIV(neg) 13%, HIV(asy) 19%, and HIV(sym) 38%). These rates remain high in subjects established on antiretroviral therapy (ART): 33% (at 6-12 months) and 52% (at 18 months), with HIV-infected individuals carrying a broader range of invasive and noninvasive serotypes compared with HIV-negative controls. The frequency of multiple serotype carriage (>1 serotype HIV(neg) 26%, HIV(asy) 30%, HIV(sym) 31%, HIV(ART) 31%) is not affected. These changes in colonization are associated with generalized CD4 T-cell depletion, impaired antigen-specific proliferation, and a defect in pneumococcal-specific T-cell interferon-γ but not interleukin 17 production. CONCLUSIONS: These data reveal the persistently poor control of pneumococcal colonization in HIV-infected adults following immune ART-mediated reconstitution, highlighting a potential reservoir for person-to-person spread and vaccine escape. Novel approaches to control colonization either through vaccination or through improvements in the quality of immune reconstitution are required.
BACKGROUND: African adults infected with human immunodeficiency virus (HIV) have high rates of pneumococcal colonization and invasive disease. Here we have investigated the possibility that HIV disrupts the normal balance of pneumococcal-specific helper T cell (Th) 1/Th17 immunity to colonization, resulting in a more permissive nasopharyngeal niche. METHODS: One hundred thirty-six HIV-infected and -uninfected Malawian adults were enrolled in the study. Changes in rates and composition of nasopharyngeal pneumococcal colonization were analyzed using microarray. The underlying pneumococcal-specific Th1/Th17 responses associated with altered pneumococcal colonization were investigated using flow cytometry. RESULTS: We find that pneumococcal carriage is only modestly increased in asymptomatic HIV-infected Malawian adults but that colonization rates rise dramatically during symptomatic disease (HIV(neg) 13%, HIV(asy) 19%, and HIV(sym) 38%). These rates remain high in subjects established on antiretroviral therapy (ART): 33% (at 6-12 months) and 52% (at 18 months), with HIV-infected individuals carrying a broader range of invasive and noninvasive serotypes compared with HIV-negative controls. The frequency of multiple serotype carriage (>1 serotype HIV(neg) 26%, HIV(asy) 30%, HIV(sym) 31%, HIV(ART) 31%) is not affected. These changes in colonization are associated with generalized CD4 T-cell depletion, impaired antigen-specific proliferation, and a defect in pneumococcal-specific T-cell interferon-γ but not interleukin 17 production. CONCLUSIONS: These data reveal the persistently poor control of pneumococcal colonization in HIV-infected adults following immune ART-mediated reconstitution, highlighting a potential reservoir for person-to-person spread and vaccine escape. Novel approaches to control colonization either through vaccination or through improvements in the quality of immune reconstitution are required.
Authors: J A Scott; A J Hall; C Muyodi; B Lowe; M Ross; B Chohan; K Mandaliya; E Getambu; F Gleeson; F Drobniewski; K Marsh Journal: Lancet Date: 2000-04-08 Impact factor: 79.321
Authors: Oluwadamilola H Iwajomo; Adam Finn; Peter Moons; Rose Nkhata; Enoch Sepako; Abiodun D Ogunniyi; Neil A Williams; Robert S Heyderman Journal: J Infect Dis Date: 2011-08-15 Impact factor: 5.226
Authors: Lovemore Gwanzura; Christopher Pasi; Kusum J Nathoo; James Hakim; Innocent Gangaidzo; Jens Mielke; Valerie J Robertson; Robert S Heyderman; Peter R Mason Journal: Int J Antimicrob Agents Date: 2003-06 Impact factor: 5.283
Authors: Kimberly A Buie; Keith P Klugman; Anne von Gottberg; Olga Perovic; Alan Karstaedt; Heather H Crewe-Brown; Shabir A Madhi; Charles Feldman Journal: J Infect Dis Date: 2004-05-12 Impact factor: 5.226
Authors: Queralt Jordano; Vicenç Falcó; Benito Almirante; Ana María Planes; Oscar del Valle; Esteve Ribera; Oscar Len; Carles Pigrau; Albert Pahissa Journal: Clin Infect Dis Date: 2004-05-12 Impact factor: 9.079
Authors: R E Hirschtick; J Glassroth; M C Jordan; T C Wilcosky; J M Wallace; P A Kvale; N Markowitz; M J Rosen; B T Mangura; P C Hopewell Journal: N Engl J Med Date: 1995-09-28 Impact factor: 91.245
Authors: Jason M Brenchley; Timothy W Schacker; Laura E Ruff; David A Price; Jodie H Taylor; Gregory J Beilman; Phuong L Nguyen; Alexander Khoruts; Matthew Larson; Ashley T Haase; Daniel C Douek Journal: J Exp Med Date: 2004-09-13 Impact factor: 14.307
Authors: Emma C Wall; Dean B Everett; Mavuto Mukaka; Naor Bar-Zeev; Nicholas Feasey; Andreas Jahn; Mike Moore; Joep J van Oosterhout; Paul Pensalo; Kenneth Baguimira; Stephen B Gordon; Elizabeth M Molyneux; Enitan D Carrol; Neil French; Malcolm E Molyneux; Robert S Heyderman Journal: Clin Infect Dis Date: 2014-02-04 Impact factor: 9.079
Authors: Joon Young Song; Hee Jin Cheong; Ji Yun Noh; Min Joo Choi; Jin Gu Yoon; Woo Joo Kim Journal: Hum Vaccin Immunother Date: 2019-08-23 Impact factor: 3.452
Authors: Daniel M Muema; Gladys N Macharia; Amin S Hassan; Shalton M Mwaringa; Greg W Fegan; James A Berkley; Eunice W Nduati; Britta C Urban Journal: J Immunol Date: 2015-06-26 Impact factor: 5.422
Authors: Arox W Kamng'ona; Jason Hinds; Naor Bar-Zeev; Katherine A Gould; Chrispin Chaguza; Chisomo Msefula; Jennifer E Cornick; Benard W Kulohoma; Katherine Gray; Stephen D Bentley; Neil French; Robert S Heyderman; Dean B Everett Journal: BMC Infect Dis Date: 2015-06-20 Impact factor: 3.090
Authors: Caroline M Weight; Simon P Jochems; Hugh Adler; Daniela M Ferreira; Jeremy S Brown; Robert S Heyderman Journal: Front Cell Infect Microbiol Date: 2021-05-25 Impact factor: 5.293
Authors: Naor Bar-Zeev; Todd D Swarthout; Dean B Everett; Maaike Alaerts; Jacquline Msefula; Comfort Brown; Sithembile Bilima; Jane Mallewa; Carina King; Anne von Gottberg; Jennifer R Verani; Cynthia G Whitney; Charles Mwansambo; Stephen B Gordon; Nigel A Cunliffe; Neil French; Robert S Heyderman Journal: Lancet Glob Health Date: 2021-07 Impact factor: 38.927
Authors: Ellen Heinsbroek; Terence Tafatatha; Amos Phiri; Bagrey Ngwira; Amelia C Crampin; Jonathan M Read; Neil French Journal: AIDS Date: 2015-09-10 Impact factor: 4.177